Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder?
Engelsk titel: Glucagon-like peptide-1 (GLP-1) analogues: A potential new treatment for alcohol use disorder? Läs online Författare: Fink-Jensen, Anders ; Vilsböll, T Språk: Eng Antal referenser: 16 Dokumenttyp: Översikt UI-nummer: 16123688

Tidskrift

Nordic Journal of Psychiatry 2016;70 (8)561-2 ISSN 0803-9488 E-ISSN 1502-4725 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

The pharmacological armamentarium for the maintenance of alcohol abstinence in patients with alcohol use disorder has not gained widespread dissemination and novel molecular targets for the medical treatment of alcohol use disorder are needed. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is secreted from endocrine L cells of the intestine in response to nutrients in the gut lumen. Recent studies have demonstrated inhibitory effects of GLP-1 analogues on alcohol consumption and alcohol-mediated behaviour in rodents. Based on the urgent need for novel pharmacological treatment strategies for alcohol use disorder and the promising pre-clinical data on the effects of GLP-1- analogues on alcohol consumption, we suggest that clinical trials rigorously testing whether GLP-1 analogues will reduce alcohol consumption in alcohol use disorder patients should be carried out.